Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 21-28

  Van Ginckel, Robert ^a   Janssens, Boudewijn ^a   Callens, Myriam ^a   Goeminne, Nick ^a   Wouters, Luc ^a   De Coster, Roland ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Aromatase; Breast cancer; Rat; Tamoxifen; Vorozole

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; AROMATASE INHIBITOR; TAMOXIFEN; VOROZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; CARCINOGENS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; LUTEINIZING HORMONE; MAMMARY NEOPLASMS, EXPERIMENTAL; OVARIECTOMY; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TRIAZOLES;

EID: 0029968393     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050442     Document Type: Article

References (23)

1. Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, Cardenal-Alemany F, Gomez-Batiste X, Fabregat-Mayol J, Viladiu-Guemada P (1988) Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer. Oncology 45: 350
2. Brodie AMH (1993) Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol Ther 60: 501
3. Brodie AMH, Marsh DA, Wu JT, Brodie HJ (1979) Aromatase inhibitors and their use in controlling oestrogen-dependent processes. J Steroid Biochem 11: 107
4. De Coster R, Van Ginckel R, Callens M, Goeminne N, Janssens B (1992) Antitumoral and endocrine effects of ( + )vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 52: 1240
5. Fendl KC, Zimniski SJ (1992) Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res 52: 235
6. Goss PE, Gwyn K (1994) Current perspectives in aromatase inhibitors in breast cancer. J Clin Oncol 12: 2460
7. Goss PE, Clark RM, Ambus U, Weizel HAE, Wadden NA, Crump M, Walde D, Tye LM, De Coster R, Bruynseels J (1995) A phase II study of vorozole (R83842). A new aromatase inhibitor in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res (in press)
8. Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rutin J, Chang MNC, Creagan ET (1986) Randomized trial of tamoxifen alone or in combination with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 4: 958
9. Inui K, Morimoto T, Komaki K, Sonoo H, Monden Y (1988) Changes in the hormone dependency of DMBA-induced rat mammary tumors with reference to the effect of tamoxifen. Jpn J Surg 18: 284
10. Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M (1994) Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54: 5875
11. Jordan VC, Murphy CS (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11: 578
12. Koziol JA, Marvell DA, Fukushima M, Comeraner ME, Pitch YH (1981) A distribution-free test for tumor-growth curve analysis with application to an animal tumor immunotherapy experiment. Biometrics 37: 383
13. Milsted R, Mabeshaw T, Kaye S, Sangstor G, Macbeth F, Campbell-Ferguson S, Smith D, Calman K (1985) A randomised trial of tamoxifen versus tamoxifen plus amino-glutethimide in postmenopausal woman with advanced breast cancer. Cancer Chemother Pharmacol 14: 272
14. Mush H (1992) Endocrine therapy for advanced breast cancer. A review. Breast Cancer Res Treat 21: 15
15. Nicholson RI, Walker KJ, Bouzoubar N, Wills RJ, Gee JM, Rushmere NK, Davies P (1990) Estrogen deprivation in breast cancer. Clinical, experimental and biological aspects. Ann NY Acad Sci 595: 316
16. Paridaens R, Piccart M, Nooy M, Klijn J, Rubens RD, Beex L, Tomiak E, Van Vreckem A, Vinholes J (1933) Phase II study of the EORTC breast group with vorozole (R83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC). Preliminary results. Eur J Cancer 29A: [Suppl 6]: S86
17. Powles TJ, Ford HT, Nash AG, Ashley S, Gazet JC, Neville AM, Coombes (1984) Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. Lancet II: 1369
18. Santen RJ, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11: 221
19. Tominaga T, Yoshida Y, Shimozuma K, Hayashi K, Kasaki G (1990) Effect of CGS/16949A plus tamoxifen on induced mammary tumours in rats. Eur J Cancer 26: 600
20. Van der Wall E, Donker TH, Frankryker E de, Nortier HWR, Thijssen JHH, Blankenstein MA (1993) Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 53: 4563
21. Wilkinson JR, Williams JC, Singh D, Goss PE, Easton D, Coombes RC (1986) Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. Cancer Res 46: 4862
22. Wouters W, Van Ginckel R, Krekels M, Bowden C, De Coster R (1993) Pharmacology of vorozole. J Steroid Biochem Mol Biol 44: 617
23. Zaccheo T, Giudici D, Di Salle E (1993) Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem 44: 677